The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Open accessAbstract
BACKGROUND: The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. METHODS: We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed. RESULTS: A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed. CONCLUSIONS: Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Self-citationChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Self-citationScher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationJames, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Self-citationAbiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Self-citationDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Self-citationAntonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 357
Self-citationOudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357
Self-citationEisenberger, M., Hardy-Bessard, A.-C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1076 · Cited by 292
Self-citationMezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds119 · Cited by 246
Self-citationEuropean cancer mortality predictions for the year 2019 with focus on breast cancer
Malvezzi, M., Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., & Negri, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz051 · Cited by 237
Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., & Basch, E. (2010) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00774.x · Cited by 224
Antonarakis, E. S., Isaacsson Velho, P., Fu, W., Wang, H., Agarwal, N., Santos, V. S., Maughan, B. L., Pili, R., Adra, N., Sternberg, C. N., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00399 · Cited by 208
Self-citationAttard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M.-E., & collaborators, O. B. O. T. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9827 · Cited by 173
Al Nakouzi, N., Le Moulec, S., Albigès, L., Wang, C., Beuzeboc, P., Gross-Goupil, M., de La Motte Rouge, T., Guillot, A., Gajda, D., Massard, C., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.015 · Cited by 164
Self-citationFitzpatrick, J. M., & de Wit, R. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.022 · Cited by 140
Morris, M. J., Molina, A., Small, E. J., Bono, J. S. D., Logothetis, C. J., Fizazi, K. S., SOUZA, P. D., Kantoff, P. W., Higano, C. S., Li, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3875 · Cited by 138
Self-citationvan Soest, R. J., de Morrée, E. S., Kweldam, C. F., de Ridder, C. M. A., Wiemer, E. A. C., Mathijssen, R. H. J., de Wit, R., & van Weerden, W. M. (2014) · European Urology · doi:10.1016/j.eururo.2014.11.033 · Cited by 135
Heidenreich, A., Sergio Bracarda, A., Mason, M. D., Özen, H., Sengeløv, L., van Oort, I. M., Papandreou, C. N., Fosså, S. D., Hitier, S., & Climent, M. Á. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.006 · Cited by 104
Beer, T. M., Hotte, S. J., Fred Saad, C., Alekseev, B. Y., Matveev, V. B., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30605-8 · Cited by 102
Self-citationAzarenko, O., Smiyun, G., Mah, J. M., Wilson, L., & Jordan, M. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0265 · Cited by 90
Bono, J. S. D., Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Small, E. J., Shore, N. D., Fizazi, K. S., Porre, P. D., Kheoh, T. S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.033 · Cited by 81
Self-citationMaines, F., Caffo, O., Veccia, A., Trentin, C., Tortora, G., Galligioni, E., & Bria, E. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.013 · Cited by 66
Maughan, B. L., Luber, B. S., Nadal, R., & Antonarakis, E. S. (2016) · The Prostate · doi:10.1002/pros.23246 · Cited by 66
van Soest, R. J., Nieuweboer, A. J. M., de Morrée, E. S., Chitu, D. A., Bergman, A. M., Goey, S. H., Bos, M. M. E. M., van der Meer, N., Hamberg, P., de Wit, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.037 · Cited by 62
Terada, N., Maughan, B. L., Akamatsu, S., Kobayashi, T., Yamasaki, T., Inoue, T., Kamba, T., Ogawa, O., & Antonarakis, E. S. (2017) · International Journal of Urology · doi:10.1111/iju.13346 · Cited by 58
Oh, W. K., Cheng, W. Y., Miao, R., Vekeman, F., Gauthier‐Loiselle, M., Duh, M. S., Drea, E., & Szatrowski, T. P. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.08.002 · Cited by 52
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
Rescigno, P., Lorente, D., Dolling, D. I., Ferraldeschi, R., Rodrigues, D. N., Riisnaes, R., Miranda, S., Bianchini, D., Zafeiriou, Z., Sideris, S., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.02.006 · Cited by 46
Miyake, H., Hara, T., Tamura, K., Sugiyama, T., Furuse, H., Ozono, S., & Fujisawa, M. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.12.015 · Cited by 42
Hall, M. E., Huelster, H. L., Luckenbaugh, A. N., Laviana, A. A., Keegan, K. A., Klaassen, Z. W. A., Moses, K. A., & Wallis, C. J. D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s228355 · Cited by 40
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation
de Morrée, E. S., van Soest, R. J., Aghai, A., de Ridder, C., de Bruijn, P., Moghaddam-Helmantel, I. M. G., Burger, H., Mathijssen, R. H. J., Wiemer, E. A. C., de Wit, R., et al. (2016) · The Prostate · doi:10.1002/pros.23182 · Cited by 39
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
Conteduca, V., Castro, E., Wetterskog, D., Scarpi, E., Jayaram, A., Romero-Laorden, N., Olmos, D., Gurioli, G., Lolli, C., Sáez, M. I., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.007 · Cited by 35
Delanoy, N., Bessard, A. C. H., Efstathiou, E., Moulec, S. L., Basso, U., Birtle, A. J., Thomson, A. H., Krainer, M., Guillot, A., Giorgi, U. D., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.05.009 · Cited by 32
Self-citationClark, E., Morton, M., Sharma, S., Fisher, H., Howel, D., Walker, J., Wood, R., Hancock, H. C., Maier, R. H., Marshall, J., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034708 · Cited by 13
Nagaya, N., Kanayama, M., Nagata, M., & Horie, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00495 · Cited by 9
Cited by
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationSurvival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citation
Metadata
- Authors
- de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., Kramer, G., Eymard, J.-C., Bamias, A., Carles, J., Iacovelli, R., Melichar, B., Sverrisdóttir, Á., Theodore, C., Feyerabend, S., Helissey, C., Ozatilgan, A., Geffriaud-Ricouard, C., & Castellano, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2506-2518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2977469640
- Cited by
- 663
- References
- 48
- FWCI
- 53.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.